Rhinosinusitis is an inflammation of the paranasal sinuses and the nasal cavity lasting no longer than 4 weeks. It can range from acute viral rhinitis (the common cold) to acute bacterial rhinosinusitis. Fewer than 5 in 1,000 colds are followed by bacterial rhinosinusitis.
Alzheimer's disease (AD) is a type of dementia that affects memory, thinking and behavior. According to the Alzheimer's Association, an estimated 6.2 million Americans are living with this progressive neurologic disorder, and it is the sixth-leading cause of death in the U.S.
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
Researchers determine the inhibition capacity of iota-carrageenan and xylitol in three different candidate preservative-free formulations.
SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible, with nasal passages being the target of original infection.
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
The millions of people who have chronic sinusitis deal not only with stuffy noses and headaches, they also commonly struggle to focus, and experience depression and other symptoms that implicate the brain's involvement in their illness.
News-Medical catches up with Professor Carl Philpott about the latest findings regarding COVID-19 and smell loss.
De'Broski Herbert has a philosophy that's guided his career researching helminths, or parasitic worms, and their interaction with their hosts' immune systems: "Follow the worm."
Researchers in the United States have demonstrated the antiviral effect of three candidate nasal spray formulations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).
Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.
Beneficial strains of bacteria residing in our guts, genital tracts, and skin have been shown to play a role in human health, and now, researchers publishing May 26 in the journal Cell Reports suggest that some of these "good" bacteria also have a niche in our noses.
Eosinophilic chronic rhinosinusitis is a type of airway disease involving nasal inflammation. Many studies have attempted to understand the molecular-based pathogenesis of recurrent ECRS; none have provided a clear explanation, until now.
Nasal saline and corticosteroid sprays are pretty standard treatment for individuals battling chronic rhinosinusitis.
For sufferers of chronic rhinosinusitis, surgery is often the only treatment option due to the severity of their condition.
Asthma and chronic rhinosinusitis- sinus inflammation that lasts for at least three months- are serious and costly diseases, and both are on the rise. According to the American Academy of Allergy, Asthma and Immunology, CRS affects up to 16 percent of the U.S. adult population and eats up a staggering 5 percent of the country's health care budget each year.
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity).
Intersect ENT, Inc., a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology, the official journal of the American Rhinologic Society, of the company's PROPEL Contour and PROPEL Mini steroid-releasing sinus implants showing improved outcomes of frontal sinus surgery.
Chronic rhinosinusitis is a common disease that is usually treated with intranasal medication and nasal saline lavage. Endoscopic sinus surgery) is considered when CRS is difficult to treat. The surgery aims to restore ventilation of paranasal sinuses and reduce inflammation.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.
A new discovery about how the immune system responds to common sinus infections and asthma could explain why patients develop these issues in the first place and ultimately may lead to improved targeted therapies.